NCT02428855View on ClinicalTrials.gov

Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma

PHASE2CompletedINTERVENTIONAL

Enrollment

8

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

February 28, 2018

Study Completion Date

February 28, 2018

Conditions

Cholangiocarcinoma

Interventions

DRUG

Dasatinib

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02215

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

TargetCancer Foundation

OTHER

lead

Massachusetts General Hospital

OTHER